A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells though MAPK activation

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Lee, Nathan V ^a   Lira, Maruja E ^a   Pavlicek, Adam ^a   Ye, Jingjing ^a,e   Buckman, Dana ^a   Bagrodia, Shubha ^a   Srinivasa, Sreesha P ^a   Zhao, Yongjun ^b   Aparicio, Samuel ^c,d   Rejto, Paul A ^a   Christensen, James G ^a   Ching, Keith A ^a  

^a PFIZER INC   (United States)

^b BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e CENTER FOR DEVICES AND RADIOLOGICAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PF 04217903; PF 04880594; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL SURVIVAL; CHROMOSOME 7Q; CHROMOSOME REARRANGEMENT; CONTROLLED STUDY; COPY NUMBER VARIATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EXON; GENE AMPLIFICATION; GENE SEQUENCE; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; STOMACH CANCER;

CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-MET; PYRAZINES; RECOMBINANT FUSION PROTEINS; TRIAZOLES;

EID: 84862697903     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039653     Document Type: Article

References (57)

1. Janne PA, Gray N, Settleman J, (2009) Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov 8: 709-723.
2. McDermott U, Pusapati RV, Christensen JG, Gray NS, Settleman J, (2010) Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency. Cancer Res 70: 1625-1634.
3. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043.
4. Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, et al. (2010) Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 29: 2346-2356.
5. Guix M, Faber AC, Wang SE, Olivares MG, Song Y, et al. (2008) Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 118: 2609-2619.
6. Comoglio PM, Giordano S, Trusolino L, (2008) Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 7: 504-516.
7. Lutterbach B, Zeng Q, Davis LJ, Hatch H, Hang G, et al. (2007) Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res 67: 2081-2088.
8. Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, et al. (2006) Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A 103: 2316-2321.
9. Cepero V, Sierra JR, Corso S, Ghiso E, Casorzo L, et al. (2010) MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. Cancer Res 70: 7580-7590.
10. Tiedt R, Degenkolbe E, Furet P, Appleton BA, Wagner S, et al. (2011) A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients. Cancer Res 71: 5255-5264.
11. Corso S, Ghiso E, Cepero V, Sierra JR, Migliore C, et al. (2010) Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. Mol Cancer 9: 121.
12. Bachleitner-Hofmann T, Sun MY, Chen CT, Tang L, Song L, et al. (2008) HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Mol Cancer Ther 7: 3499-3508.
13. Bertotti A, Burbridge MF, Gastaldi S, Galimi F, Torti D, et al. (2009) Only a subset of Met-activated pathways are required to sustain oncogene addiction. Sci Signal 2: er11.
14. Herrick J, Michalet X, Conti C, Schurra C, Bensimon A, (2000) Quantifying single gene copy number by measuring fluorescent probe lengths on combed genomic DNA. Proc Natl Acad Sci U S A 97: 222-227.
15. Kuruma H, Kamata Y, Takahashi H, Igarashi K, Kimura T, et al. (2009) Staphylococcal nuclease domain-containing protein 1 as a potential tissue marker for prostate cancer. Am J Pathol 174: 2044-2050.
16. Tsuchiya N, Nakagama H, (2010) MicroRNA, SND1, and alterations in translational regulation in colon carcinogenesis. Mutat Res 693: 94-100.
17. Tsuchiya N, Ochiai M, Nakashima K, Ubagai T, Sugimura T, et al. (2007) SND1, a component of RNA-induced silencing complex, is up-regulated in human colon cancers and implicated in early stage colon carcinogenesis. Cancer Res 67: 9568-9576.
18. Li CL, Yang WZ, Chen YP, Yuan HS, (2008) Structural and functional insights into human Tudor-SN, a key component linking RNA interference and editing. Nucleic Acids Res 36: 3579-3589.
19. Santhekadur PK, Das SK, Gredler R, Chen D, Srivastava J, et al. (2012) The multifunction protein, Staphylococcal Nuclease Domain Containing-1 (SND1), promotes tumor angiogenesis in human hepatocellular carcinoma through a novel pathway which involves NF-kappaB and miR-221. Journal of Biological Chemistry.
20. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, et al. (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116: 855-867.
21. Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, et al. (2008) BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. Journal of Clinical Endocrinology and Metabolism 93: 3943-3949.
22. Li WQ, Kawakami K, Ruszkiewicz A, Bennett G, Moore J, et al. (2006) BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer 5: 2.
23. Gear H, Williams H, Kemp EG, Roberts F, (2004) BRAF mutations in conjunctival melanoma. Investigative Ophthalmology and Visual Science 45: 2484-2488.
24. Jones DT, Kocialkowski S, Liu L, Pearson DM, Backlund LM, et al. (2008) Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 68: 8673-8677.
25. Dessars B, De Raeve LE, El Housni H, Debouck CJ, Sidon PJ, et al. (2007) Chromosomal translocations as a mechanism of BRAF activation in two cases of large congenital melanocytic nevi. J Invest Dermatol 127: 1468-1470.
26. Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z, et al. (2005) Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest 115: 94-101.
27. Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pflueger D, Ramnarayanan K, et al. (2010) Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 16: 793-798.
28. Brown AP, Carlson TC, Loi CM, Graziano MJ, (2007) Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration. Cancer Chemotherapy and Pharmacology 59: 671-679.
29. Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, et al. (2006) Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 5: 2676-2684.
30. Sarkar D, (2008) Lattice multivariate data visualization with R. xvii, 265 p New York; London Springer Science+Business Media.
31. Ritz C, Streibig JC, (2005) Bioassay Analysis using R. Journal of Statistical Software 12: 1-22.
32. Wu Z, Irizarry RA, Gentleman R, Martinez-Murillo F, Spencer F, (2004) A Model-Based Background Adjustment for Oligonucleotide Expression Arrays. Journal of the American Statistical Association 99: 909-917.
33. Bengtsson H, Irizarry R, Carvalho B, Speed TP, (2008) Estimation and assessment of raw copy numbers at the single locus level. Bioinformatics 24: 759-767.
34. Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, et al. (2009) Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461: 809-813.
35. Morin R, Bainbridge M, Fejes A, Hirst M, Krzywinski M, et al. (2008) Profiling the HeLa S3 transcriptome using randomly primed cDNA and massively parallel short-read sequencing. Biotechniques 45: 81-94.
36. Li H, Durbin R, (2009) Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25: 1754-1760.
37. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, et al. (2009) The Sequence Alignment/Map format and SAMtools. Bioinformatics 25: 2078-2079.
38. Zeitouni B, Boeva V, Janoueix-Lerosey I, Loeillet S, Legoix-ne P, et al. (2010) SVDetect: a tool to identify genomic structural variations from paired-end and mate-pair sequencing data. Bioinformatics 26: 1895-1896.
39. Zerbino DR, Birney E, (2008) Velvet: algorithms for de novo short read assembly using de Bruijn graphs. Genome Res 18: 821-829.
40. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ, (1990) Basic local alignment search tool. Journal of Molecular Biology 215: 403-410.
41. Longati P, Bardelli A, Ponzetto C, Naldini L, Comoglio PM, (1994) Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor). Oncogene 9: 49-57.
42. Zhong S, Delva L, Rachez C, Cenciarelli C, Gandini D, et al. (1999) A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RARalpha and T18 oncoproteins. Nat Genet 23: 287-295.
43. Mason CS, Springer CJ, Cooper RG, Superti-Furga G, Marshall CJ, et al. (1999) Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. Embo J 18: 2137-2148.
44. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, et al. (2010) RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464: 431-435.
45. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N, (2010) RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464: 427-430.
46. Sawyers C, (2004) Targeted cancer therapy. Nature 432: 294-297.
47. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, et al. (2007) Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A 104: 19936-19941.
48. Sebolt-Leopold JS, English JM, (2006) Mechanisms of drug inhibition of signalling molecules. Nature 441: 457-462.
49. Goodall J, Wellbrock C, Dexter TJ, Roberts K, Marais R, et al. (2004) The Brn-2 transcription factor links activated BRAF to melanoma proliferation. Mol Cell Biol 24: 2923-2931.
50. Bertotti A, Bracco C, Girolami F, Torti D, Gastaldi S, et al. (2010) Inhibition of Src impairs the growth of met-addicted gastric tumors. Clin Cancer Res 16: 3933-3943.
51. Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, et al. (2009) In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clinical Cancer Research 15: 4649-4664.
52. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, et al. (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18: 683-695.
53. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, et al. (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468: 968-972.
54. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, et al. (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468: 973-977.
55. Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, et al. (2012) EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2: 227-235.
56. Yip L, Kelly L, Shuai Y, Armstrong MJ, Nikiforov YE, et al. (2011) MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Annals of Surgical Oncology 18: 2035-2041.
57. Vergani E, Vallacchi V, Frigerio S, Deho P, Mondellini P, et al. (2011) Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032. Neoplasia 13: 1132-1142.